Hansa Biopharma 2022 Cowen Health Care Conference Presentation

Hansa Biopharma presents investor overview of its rare immunologic disease portfolio at the 2022 Cowen Annual Health Care Conference. The company has achieved European approval of Idefirix for kidney transplantation and maintains a pipeline spanning transplantation and autoimmunity indications. With validated technology across multiple therapeutic areas and recent capital raised, Hansa is positioned through 2023.